DIRS.INFO The most relevant business & tech news

☆ How to dance the earnings two-step: Recognize initial stock distortions and then act
▼ + stars: | 2024-10-27 | by ( Jim Cramer | ) www.cnbc.com time to read: +18 min

For all we know, the yield curve may simply be going through the birthing of an un-inverted yield curve. GOOGL YTD mountain Alphabet YTD Search used to be so simple. META YTD mountain Meta Platforms YTD Meta Platforms has run big ahead of the quarter. AMZN YTD mountain Amazon YTD Let's get to the two toughest of the week, Amazon and Apple. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: let's, Eli Lilly, nonfarm payrolls, Carl Quintanilla, batty, Jeff Marks, Waymo, Elon Musk, Donald Trump, Kamala Harris, Department's, Mark Zuckerberg, Jensen Huang, Marc Benioff, Trump, Warren Buffett, Jim Cramer's, Jim Cramer, Jim Organizations: CNBC, Microsoft, Apple, Treasury, Federal Reserve, charlatans, Honeywell, Twitter, Club, Gemini, YouTube, Google, Donner Party of cannibalization, AMD, Nvidia, Intel, Merck, Pfizer, Tech Titans, Meta, Amazon Web Services Locations: Wall, cyclicals, California, Philly

☆ 14 earnings reports and major economic data will be the stock market movers this week
▼ + stars: | 2024-10-27 | by ( Zev Fima | ) www.cnbc.com time to read: +15 min

The Street is looking for Stanley Black & Decker sales of $3.8 billion in the third quarter and earnings per share (EPS) of $1.05. The Street is looking for Linde sales of $8.35 billion in the third quarter and EPS of $3.89. In addition to the headline results and forward guidance, overall organic sales growth and data center energy power demand will be focus items for investors. The Street is looking for sales of $94.47 billion in its fiscal fourth quarter and EPS of $1.55. The Street is looking for Coterra sales of $1.3 billion in the third quarter and EPS of 34 cents.

Persons: That's, It's, Stanley Black, Decker, we're, We're, Eli Lilly, Lilly, Amy Hood's, Brian Niccol, Wednesday's, Linde, it's, we'll, Phillips, Horton, Kraft Heinz, SIRI, Estee Lauder, BUD, Cardinal Health, Jim Cramer's, Jim Cramer, Jim, Stephanie Keith Organizations: Nasdaq, Dow, Fed, PCE, YouTube, Justice, AMD, GE Healthcare, Reality Labs, Microsoft, Management, Starbucks, U.S, Presidential, Linde, Apple Intelligence, Amazon, Services, Coterra Energy, WM, Cadence Design Systems, Labor, PayPal, BP, Pfizer, Royal Caribbean Cruises, JetBlue, HSBC, Devices, Grill, Electronic Arts, EA, Gross, Caterpillar, Brinker International, AFortive Corporation, Illinois Tool, Coinbase, eBay, EBAY, Booking Holdings, MGM Resorts, MGM, Bausch Health, LIN, Merck, ConocoPhillips, Mastercard, Altria, Cruise, Myers Squibb, Comcast, Mobileye, Cheniere Energy, Regeneron Pharmaceuticals, Anheuser, Busch InBev, Intel, United States Steel, Juniper Networks, Chevron, Exxon Mobil, Dominion Energy, Charter Communications, LyondellBasell Industries, Cardinal, Jim Cramer's Charitable, CNBC, New York Stock Exchange, Getty Locations: Eaton, Corning, Illinois, Bristol, New York City

☆ Earnings playbook: Busiest week of the season includes reports from megacaps Apple and Amazon
▼ + stars: | 2024-10-27 | by ( Fred Imbert | ) www.cnbc.com time to read: +7 min

Monday Ford Motor is set to report earnings after the bell, followed by a conference call at 5 p.m. What history shows: Bespoke Investment Group data shows Ford beats earnings expectations 68% of the time. What to watch: Meta is in a good spot heading into this week's report, according to Bernstein's Mark Shmulik. Microsoft is set to report earnings after the close, with a conference call on deck for 5:30 p.m. Amazon is set to report earnings after the market close, with a conference call at 5 p.m.

Persons: Edison Yu, Yu, BioNTech, Goldman Sachs, Toshiya Hari, Hari, LSEG, Bernstein's Mark Shmulik, Morgan Stanley's Keith Weiss, AAPL, KeyBanc, Justin Post Organizations: Apple, Ford Motor . Pharmaceutical, Pfizer, Corporate America, Monday Ford, LSEG, Ford, AMD, Cloud Service, Google, Microsoft, Windows, CNBC, Management, Amazon Web Services, Bank of America, Amazon Locations: Temu, .

☆ Wall Street braces for a big week ahead of the election, with megacap tech earnings, key data on tap
▼ + stars: | 2024-10-25 | by ( Sarah Min | ) www.cnbc.com time to read: +5 min

Investors will contend with earnings results from five of the Magnificent Seven companies next week. .SPX 1M mountain S & P 500 "I sort of refer to this period that we're in right now as like a strange brew," said Mark Malek, investment chief at Siebert. On Friday, the Nasdaq Composite hit an all-time high , but the S & P 500 snapped a six-week win streak. In fact, the high concentration of the mega-cap leaders in the S & P 500 spurred Goldman Sachs' David Kostin this month to release a dim long-term forecast for the overall market. HSBC head of equity strategy Nicole Inui upped her S & P 500 year-end target to 5,900.

Persons: Mark Malek, Siebert, Goldman Sachs, David Kostin, Siebert's Malek, they've, Nicole Inui, Inui, D.R Horton, Price, Eli Lilly, Lauder Organizations: Microsoft, Meta, Apple, Nasdaq, U.S, Treasury, Big Tech, HSBC, FactSet, Richmond Fed, Dallas Fed, Ford, Semiconductor, Caesars Entertainment, Devices, Pfizer, Royal Caribbean Group, PayPal, ADP, Kraft Heinz, Caterpillar, GE Healthcare Technologies, Holdings, ECI Civilian Workers, PCE, PCE Deflator, Chicago PMI, Cruise Line Holdings, Uber Technologies, Lauder Companies, Mastercard, Generac, Jobs, PMI, Manufacturing, Exxon Mobil Locations: U.S, Chicago

☆ What activist hedge fund Starboard wants from Pfizer
▼ + stars: | 2024-10-22 | by ( Alex Nicoll | Kaja Whitehouse | ) www.businessinsider.com time to read: +3 min

Activist hedge fund Starboard has taken a stake in drug giant Pfizer. AdvertisementActivist hedge fund manager Jeff Smith outlined his concerns about drugmaker Pfizer on Tuesday but stopped short of offering a solution — saying that's a job for the board of directors. He also shared a version of the presentation his hedge fund Starboard presented to Pfizer officials at a meeting last week. "We all get measured by our track record," Smith told the crowd. The track record is not great during this period of time in the pharma industry."

Persons: execs, —, Jeff Smith, Smith, Pfizer, It's, I'm Organizations: Pfizer, Service, 13D, pharma Locations: Manhattan, Central, Olive Garden

Kenvue CEO Thibaut Mongon at the New York Stock Exchange for its initial public offering, May 4, 2023. Activist investor Starboard Value has a large stake in Kenvue , which spun out of Johnson & Johnson in mid-2023, according to people familiar with the matter. Starboard's push at Kenvue comes just two weeks after news broke it had amassed a roughly $1 billion stake in struggling pharmaceutical company Pfizer. Johnson & Johnson completed its separation from Kenvue in August last year, though the pharmaceutical giant still holds a stake in the new company. Kenvue started trading on the New York Stock Exchange in May 2023, ending its first day of trading with a share price of about $27.

Persons: Thibaut Mongon, Johnson, Starboard's Jeff Smith, J's, Haleon, Kenvue Organizations: New York Stock Exchange, CNBC, Wall Street, Pfizer, Johnson, J, Procter Locations: Kenvue

☆ Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
▼ + stars: | 2024-10-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Merck plans to discuss the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season, according to a release. The trial examined the safety and efficacy of a single dose of the treatment, clesrovimab, in healthy preterm and full-term infants entering their first RSV season. Results were consistent through both the five-month and six-month time points in the trial, Merck said. Merck's clesrovimab could potentially compete against a similar treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide last RSV season due to unprecedented demand. But Merck's treatment can be administered to infants regardless of their weight, which the company said may offer convenience in terms of dosing.

Persons: Merck, Clesrovimab, Dr, Octavio Ramilo, Ramilo, Merck's Organizations: Merck, New York Stock Exchange, Infectious, Research, Sanofi, AstraZeneca, Pfizer, GSK Locations: Los Angeles, St

☆ Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge
▼ + stars: | 2024-10-16 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Novavax on Wednesday said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a standalone flu vaccine, sending the company's shares down sharply. A clinical hold is an order issued by the FDA to a manufacturer to delay or suspend a proposed clinical investigation on a drug. Still, it appears to be a setback for the biotech company, which is scrambling to bring new products to market as demand for its Covid vaccine plummets worldwide. Novavax said it was working with the FDA to resolve the clinical hold on its combination shot and standalone flu vaccine. Novavax's shot, meanwhile, fends off the virus with protein-based technology, a decades-old method used in routine vaccinations against hepatitis B and shingles.

Persons: Novavax, Dr, Robert Walker, Novavax's, fends Organizations: Dutch Health Service Organization, Food and Drug Administration, FDA, Public, Pfizer, Moderna, Covid Locations: The Hague, Netherlands

☆ CNBC Daily Open: A dovish Fed is driving markets. Keep an eye out for roadblocks
▼ + stars: | 2024-10-10 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Close to record close for NvidiaNvidia shares have rallied 25% in the last month and are currently trading at $132.11. Former Tata Sons chairman passes awayRatan Tata, the former chairman of the Indian conglomerate Tata Sons, passed away on Wednesday, aged 86. As chairman, Tata was instrumental in spearheading over 60 global acquisitions, helping to grow the group's revenue past $100 billion during his tenure.

Persons: Ian Read, Frank D'Amelio, D'Amelio, Ratan Tata, Tata Organizations: CNBC, Dow Jones, Technology, Nasdaq, Nvidia Nvidia, Nvidia, Microsoft, Mizuho, Pfizer, Guggenheim Securities, Former Tata, Tata Sons, IA Locations: Asia, Pacific, Hong Kong, OpenAI

Ian Read, chairman and chief executive officer of Pfizer Inc., gestures as he speaks during a panel session at the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, Jan. 17, 2017. Activist Starboard Value accused Pfizer of threatening litigation against the company's former CEO and CFO in order to get them to break ranks with the investor's nascent turnaround campaign at the pharmaceutical giant. Pfizer shares slipped overnight as news of the two executive's breakaway emerged, and opened down roughly 2.5% in Thursday morning trading. Starboard's Smith said that when the activist approached the two executives, both expressed "concerns" about Pfizer's direction under Bourla and offered to help Starboard in its turnaround campaign. Starboard's Smith and Bourla are slated to meet in person next week, Smith said, confirming earlier reports.

Persons: Ian Read, Pfizer, Jeff Smith, Frank D'Amelio's, Smith, Albert Bourla, Starboard's Smith Organizations: Pfizer Inc, Economic, Pfizer Locations: Davos, Switzerland

☆ Former Pfizer CEO, finance chief step back from Starboard's activist campaign
▼ + stars: | 2024-10-10 | by ( Rohan Goswami | In Rohangoswamicnbc | ) www.cnbc.com time to read: +2 min

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said Wednesday evening that they would step away from Starboard Value's campaign at the struggling pharmaceutical giant, just days after news of the activist's stake broke. Read and D'Amelio said they were "fully supportive" of Pfizer CEO Albert Bourla in a joint statement made via an investment bank and confirmed to be authentic. The duo had been in contact with a number of directors shortly before news of Starboard's stake broke Sunday evening, according to people familiar with the matter. For executives to join, and then walk away from an activist's campaign is highly unusual. It was also not immediately clear what impact, if any, the breakaway would have on Starboard's campaign.

Persons: Ian Read, Donald Trump, Frank D'Amelio, Read, D'Amelio, Albert Bourla, Jeff Smith, Bourla Organizations: Pfizer, White, Washington , D.C, Guggenheim Securities, dealmaking, CNBC, Autodesk, Wall Street, Corp Locations: Washington ,

☆ Jim Cramer looks at a buy level for this industrial AI play, says be patient on Costco
▼ + stars: | 2024-10-10 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. With third-quarter earnings starting in earnest Friday, Jim Cramer urged investors to keep their "eye on the prize." As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jim, Eaton, he's, he'd, Hurricane Helene, Stocks, Jim Cramer's, DOV Organizations: CNBC, Wells, JPMorgan, Honeywell, Costco, Delta Air Lines, Nike, Pfizer, DD Locations: Dupont, Dover, U.S

☆ GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
▼ + stars: | 2024-10-09 | by ( ) edition.cnn.com time to read: +3 min

CNN —GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday. GSK also said it would pay $70 million to settle a related whistleblower lawsuit filed by a Connecticut laboratory. Pfizer has agreed to settle most of the Zantac cases against it in state court, according to its most recent financial statement, and Sanofi in April announced that it was settling about 4,000 cases. Boehringer Ingelheim has not announced any major settlements, but is currently facing a trial over the drug in Oakland, California, state court. A majority of the remaining state court cases are in Delaware, where a judge in June allowed plaintiffs to present crucial expert testimony that Zantac caused cancer.

Persons: Jennifer Moore, Brent Wisner, Zantac, Boehringer Ingelheim, “, ” Moore, Wisner Organizations: CNN, GSK, Pfizer, Sanofi, Boehringer, Food and Drug Administration, Delaware Supreme Court Locations: Connecticut, Oakland , California, Delaware, Florida

☆ Stocks making the biggest moves midday: Generac, Amazon, Pfizer and more
▼ + stars: | 2024-10-07 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Generac Holdings — Shares of the maker of power generators surged 8% as Hurricane Milton intensified into a Category 5 storm . Amazon — The e-commerce stock lost 2.9% after Wells Fargo downgraded shares to equal weight from overweight and cut its price target, citing slowing growth and competition from Walmart. Hershey – Shares fell 2% after the chocolate maker was downgraded to neutral at UBS and to market perform at Bernstein. JPMorgan downgraded shares to underweight from neutral, citing dwindling confidence in the Israel-based company grapples with share loss concerns and volume challenge. JPMorgan downgraded shares to neutral, citing limited EPS upside from here.

Persons: Milton, Wells, Chubb, Morgan Stanley, Coty, Ashley Helgans, Arcadium, Bernstein, GLP, Ciena, —, Yun Li, Hakyung Kim, Alex Harring, Jesse Pound, Michelle Fox, Sean Conlon, Pia Singh Organizations: Generac Holdings, Walmart, Pfizer —, CNBC, Insurance, —, Allstate, Travelers, Progressive, Hurricane, Universal Insurance, Air Products, Chemicals, Garmin —, Garmin, Jefferies, Rio Tinto, Hershey –, UBS, Butterfly Equity, JPMorgan, Apple Locations: Florida, Hurricane Milton, Fort Lauderdale , Florida, Wells Fargo, California, Israel

☆ Stocks making the biggest moves premarket: Apple, Amazon, Pfizer, Hershey and more
▼ + stars: | 2024-10-07 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +2 min

NXP Semiconductor — Shares added 0.8% after UBS upgraded the chipmaker to buy from neutral. Amazon — Shares slumped nearly 2% after Wells Fargo downgraded the e-commerce company to equal weight from overweight, citing slowing growth and competition from Walmart. Pfizer — Activist investor Starboard Value took a roughly $1 billion stake , seeking a turnaround at the struggling company, sources told CNBC. American Express — The financial services stock fell more than 1% after JPMorgan downgraded shares to neutral from overweight. Ally Financial — The financial services stock added 1.4% on the back of a JPMorgan upgrade to overweight from neutral.

Persons: Jefferies, Wells, Coty, Ashley Helgans, Bernstein, headwinds, Ally, Yun Li, Samantha Subin, Alex Harring, Pia Singh, Michelle Fox Organizations: —, Semiconductor, UBS, Walmart, Pfizer —, CNBC, Jefferies, Hershey, American Express, JPMorgan, Wynn Resorts, United Locations: Wells Fargo, underperform, GLP, United Arab Emirates

☆ Pfizer needs to 'fix what they have', no M&A capacity, says BMO's Evan Seigerman on activist stake
▼ + stars: | 2024-10-07 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer needs to 'fix what they have', no M&A capacity, says BMO's Evan Seigerman on activist stakeEvan David Seigerman, BMO Biotech Analyst, joins 'Closing Bell Overtime' to talk Pfizer shares climbing on activist firm Starboard taking a stake in the company.

Persons: BMO's Evan Seigerman, Evan David Seigerman Organizations: Pfizer, BMO Biotech Analyst

☆ Jim Cramer says Abbott Labs picked up a 'very big win' — here's where the stock is going
▼ + stars: | 2024-10-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Oil prices also continued their climb higher on escalating tensions in the Middle East — though Jim Cramer cautioned investors against chasing the concurrent rally in energy stocks at this point. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, downgrades, We'll, Morgan Stanley, Wells Fargo, Jim, Abbott, Louis, Stocks, Jim Cramer's Organizations: CNBC, Apple, DuPont, Constellation Brands, Federal, U.S, Bank, Abbott Laboratories, FDA, CDC, NIH, Abbott Labs, Pfizer, American Express, KB, Netflix, Air Products, Chemicals, Jim Cramer's Charitable Locations: U.S, St

☆ Activist Starboard Value has $1 billion Pfizer stake, taps former executives for help, sources say
▼ + stars: | 2024-10-07 | by ( Rohan Goswami | In Rohangoswamicnbc | ) www.cnbc.com time to read: +2 min

Activist investor Starboard Value has a roughly $1 billion stake in pharmaceutical giant Pfizer and is seeking to mount a turnaround at the struggling company, according to people familiar with the matter. Starboard believes that Pfizer's current leadership, under CEO Albert Bourla, has stepped away from historically disciplined cost structure and investment in novel drugs. One particularly concerning example to Starboard was Pfizer's acquisition of Global Blood Therapeutics. Pfizer pulled a drug for sickle cell disease it got just two years ago via the roughly $5 billion acquisition. Still, more than $100 billion in shareholder value has evaporated since the Covid-19 pandemic faded largely into the rearview mirror.

Persons: Ian Read, Frank D'Amelio, Albert Bourla, Oxbryta, Read, Jeff Smith, Angelica Peebles Organizations: Pfizer, Blood Therapeutics, Autodesk, Street

☆ The human life span may have finally plateaued. Here's what you can do to optimize your chances for a long life — and what researchers are working on next.
▼ + stars: | 2024-10-07 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +7 min

download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . Life expectancy in the US shot up at a rate of about three years per decade in the last century: from roughly age 47 in 1900 to age 77 in 2000. As more people in wealthy countries make it to old age, human life expectancy gains are nearing a plateau. The study tracks trends in their death rates and life expectancy from 1990 to 2019, before the COVID-19 pandemic started. Spending just 3% of your day exercising can mean you stay healthier for longer, an expert in healthy aging said.

Persons: —, Jay Olshansky, We've, Mick Jagger, Joe Biden, Kevin Winter, Thomas Barwick, Olskansky, Olshansky, Aubrey de Grey, De Grey, Peter Fedichev, Gero, hasn't, Fedichev Organizations: Service, Aging, University of Illinois, Business, Pfizer Locations: Chicago, Australia, France, Italy, Japan, South Korea, Spain, Sweden, Switzerland, Hong Kong

☆ Activist investor Starboard has just informed Pfizer it has taken a significant stake
▼ + stars: | 2024-10-07 | by ( Alex Morrell | ) www.businessinsider.com time to read: +1 min

Starboard Value has taken a significant stake in Pfizer, said people familiar with the matter. Starboard has recently taken positions in Starbucks and Match. The activist investor has informed Pfizer that it has taken a significant stake in the drugmaker, people familiar with the matter told Business Insider. The Wall Street Journal earlier reported the Starboard stake. It also has a stake in Rupert Murdoch's News Corp and has pushed for a breakup of the media conglomerate.

Persons: — Organizations: Pfizer, Service, pharma, Street, Rupert Murdoch's News Corp

☆ Meet Jeff Smith, the hedge-fund investor taking on Pfizer
▼ + stars: | 2024-10-07 | by ( Alex Morrell | ) www.businessinsider.com time to read: +7 min

Starboard Value has taken a $1 billion stake in drugmaker Pfizer. The hedge fund, headed by Jeff Smith, has become one of the most feared activist investors. AdvertisementPharmaceuticals giant Pfizer got a wake up call Sunday evening when one of Wall Street's most feared activist investors revealed a stake in the company. AdvertisementPfizer, with a market cap north of $160 billion, is among the largest companies Starboard's Smith has ever targeted. With less than a 10% stake Smith replaced the entire 12-person board and assumed the role of chairman.

Persons: Jeff Smith, —, Smith, Starboard's Smith, Ian Read, Frank D'Amelio, Ken Squire, Paul Singer, Elliott, Carl Icahn, Dan Loeb, Peter Feld, Olive Garden's, Marc Benioff, Brontë Wittpenn, Brontë, Squire, they're, Albert Bourla, Bourla, wagered Organizations: Pfizer, Service, Pharmaceuticals, 13D, Investor, Lazard, Elliott Management, Icahn Enterprises, Cowen Group, AOL, Darden Restaurants, Olive Garden, Longhorn, Darden, Wall, San Francisco, Getty, Smithfield Foods, Bristol, Myers Squibb, Celgene, Autodesk, Starbucks Locations: Olive Garden, Fortune, America, Olive, Washington

☆ Starboard's stake in Pfizer 'doesn't make any sense to me at all', says Dartmouth's Paul Argenti
▼ + stars: | 2024-10-07 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailStarboard's stake in Pfizer 'doesn't make any sense to me at all', says Dartmouth's Paul ArgentiPaul Argenti, Dartmouth Tuck School of Business professor, joins 'Squawk Box' to discuss news of activist investor Starboard Value amassing a roughly $1 billion stake in drugmaker Pfizer, whether Pfizer makes sense as an activist target, and more.

Persons: Dartmouth's Paul Argenti Paul Argenti Organizations: Pfizer, Dartmouth Tuck School of Business

☆ Chart of the Day: Pfizer
▼ + stars: | 2024-10-07 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailChart of the Day: PfizerStarboard takes a $1 billion stake in $PFE. It's our Chart Of The Day. The Investment Committee discuss healthcare and biotech stocks.

Organizations: Pfizer

☆ Earnings season kicks off after a blowout jobs report upended investors' hopes of another interest-rate cut
▼ + stars: | 2024-10-07 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

Tech: Amazon's Prime Day kicks off tomorrow, and there are some deals on surprising items . Amazon's Prime Day kicks off tomorrow, and there are some deals on . Getty Images; Jenny Chang-RodriguezWe've already got one indication companies are in good shape: Friday's blockbuster jobs report . But another blowout report — 250,000 jobs added and at least 4% wage growth — could lead the Fed to reconsider its easing policy. In addition to the usual Prime Day gadgets, like TVs and Airpods, Amazon is dishing out deals on tents, pocket knives, and chainsaws.

Persons: —, Jenny Chang, Rodriguez, Matthew Fox, we'll, Rodriguez We've, there's, Philipp Carlsson, Chelsea Jia Feng, haven't, Donald Trump's, Tyler Le, John Tomac, that's, boomers, They're, Gen Xers, Gen Zers, Kamala Harris, Dan DeFrancesco, Jordan Parker Erb, Hallam Bullock, Grace Lett, Amanda Yen, Milan Sehmbi Organizations: Business, Service, . Tech, Amazon's, Pfizer, Wall Street, JPMorgan, Wells Fargo, Big Tech, Getty, Fed, Boston Consulting, Trump Media, Microsoft, BI, pharma, CBS, ASEAN Locations: Israel, fintech, Vientiane, Laos, New York, London, Chicago

☆ Cheap stocks to buy in the fourth quarter, according to HSBC
▼ + stars: | 2024-10-05 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

It's officially a new trading month, and HSBC recommends investors broaden their exposure in the fourth quarter by seeking out stocks with more reasonable valuations. "These 'big' companies represent the lion's share of equity index returns year to date." HSBC has a buy rating on the stock. In all, 16 of the 29 analysts covering GM have a strong buy or buy rating, and its average price target of $54.35 implies nearly 19% upside from Friday's close, per LSEG. The remaining 11 have a buy or strong buy rating.

Persons: It's, Nicole Inui, General Motors, Goldman Sachs, Goldman Organizations: HSBC, Dow, Industrial, Nasdaq, Federal Reserve, General, GM, Pharmaceutical, Pfizer, Delta Air Lines Locations: Americas, U.S

Search resuls for: "Pfizer"

25 mentions found